dichlororibofuranosylbenzimidazole has been researched along with B-Cell Lymphoma in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lam, LT | 1 |
| Pickeral, OK | 1 |
| Peng, AC | 1 |
| Rosenwald, A | 1 |
| Hurt, EM | 1 |
| Giltnane, JM | 1 |
| Averett, LM | 1 |
| Zhao, H | 1 |
| Davis, RE | 1 |
| Sathyamoorthy, M | 1 |
| Wahl, LM | 1 |
| Harris, ED | 1 |
| Mikovits, JA | 1 |
| Monks, AP | 1 |
| Hollingshead, MG | 1 |
| Sausville, EA | 1 |
| Staudt, LM | 1 |
1 other study available for dichlororibofuranosylbenzimidazole and B-Cell Lymphoma
| Article | Year |
|---|---|
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.
Topics: Antineoplastic Agents; Dactinomycin; Dichlororibofuranosylbenzimidazole; Flavonoids; Gene Expression | 2001 |